Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo MDI with spacerDrug: Placebo MDI without spacer
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 92
- Registration Number
- NCT01258803
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 157
- Registration Number
- NCT01244828
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Phase 3
Completed
- Conditions
- Bipolar Disorder, Pediatric
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 404
- Registration Number
- NCT01244815
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
Phase 1
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: Ezetimibe/atorvastatin 10mg/80mg FDCDrug: Ezetimibe/atorvastatin 10mg/10mg FDC
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 200
- Registration Number
- NCT01236430
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: Placebo to Etoricoxib 60 mgDrug: Placebo to Etoricoxib 90 mg
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1404
- Registration Number
- NCT01208181
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
Phase 3
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Drug: Part I - etoricoxib 60 mgDrug: Part I- naproxen 1000 mgDrug: Part I - etoricoxib 90 mgDrug: Part I - Placebo to naproxen 500 mgDrug: Part II- naproxen 1000 mgDrug: Part II- etoricoxib 60 mgDrug: Part I - Placebo to etoricoxib 60 mgDrug: Part II- etoricoxib 90 mgDrug: Part I - Placebo to etoricoxib 90 mgDrug: Part II - Placebo to etoricoxib 90 mgDrug: Part II- Placebo to etoricoxib 60 mgDrug: Part II- Placebo to naproxen 500 mg
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1015
- Registration Number
- NCT01208207
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
Phase 1
Completed
- Conditions
- SchizophreniaBipolar I Disorder
- Interventions
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 30
- Registration Number
- NCT01206517
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
Phase 3
Completed
- Conditions
- Schizophrenia, ParanoidSchizophrenia, DisorganizedSchizophrenia, Undifferentiated
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 204
- Registration Number
- NCT01190267
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
Phase 3
Completed
- Conditions
- Schizophrenia, DisorganizedSchizophrenia, ParanoidSchizophrenia, Undifferentiated
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 306
- Registration Number
- NCT01190254
Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)
Completed
- Conditions
- Contraception
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1919
- Registration Number
- NCT01181778